- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.11.25 | Agios shares fall on mixed sickle cell results for blood disease drug | ||
| 19.11.25 | UnitedHealth adds former FDA commissioner Scott Gottlieb to board | ||
| 19.11.25 | Alkermes escalates bidding war; US biotech risks 'falling behind' China | ||
| 18.11.25 | RNAi biotech Arrowhead wins first FDA approval | ||
| 18.11.25 | Roche pill notches win in early breast cancer | ||
| 18.11.25 | Merck's blockbuster-to-be cardiovascular drug scores in another heart study | ||
| 18.11.25 | Zymeworks to change course, pursue 'royalty-driven' biotech model | ||
| 17.11.25 | J&J adds to pharma's M&A spree with $3B buyout of startup Halda | ||
| 17.11.25 | FDA limits Elevidys use; Nxera to lay off staff | ||
| 17.11.25 | A 'DNA damage repair' drugmaker raises $115M for cancer treatments | ||
| 17.11.25 | Solve lines up $120M to push ADCs into further testing | ||
| 17.11.25 | The inspection-ready operating model for clinical trials | ||
| 17.11.25 | Securing quality in every dose: 5 essential capabilities for CGT developers to look for in a fill-finish CDMO | ||
| 17.11.25 | Sofinnova Partners raises another $750M to back biotech, medtech startups | ||
| 14.11.25 | To Wall Street, a new bidding war puts Alkermes in a tough spot | ||
| 14.11.25 | Bristol Myers, J&J's new blood thinner fails first big test | ||
| 14.11.25 | Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal | ||
| 14.11.25 | Merck stakes $9.2B on Cidara and its long-acting flu drug | ||
| 14.11.25 | Medicxi closes fifth fund to back 'asset-centric' startups | ||
| 13.11.25 | Day One snaps up ADC maker Mersana in backloaded buyout deal | ||
| 13.11.25 | Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing | ||
| 12.11.25 | Novartis, with study success, to seek approval of new kind of malaria drug | ||
| 12.11.25 | FDA unveils new regulatory roadmap for bespoke drug therapies | ||
| 12.11.25 | Richard Pazdur, longtime FDA oncology leader, to head agency's main drug office | ||
| 12.11.25 | Metagenomi, Ovid CEOs step aside; Cogent soars on 'unprecedented' stomach cancer data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.